Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19467894 | 0.88 | GABRA1 (0.63) | FGFR1HTTSRC | |
| SCHEMBL19915930 | 0.86 | FGFR1 (0.62) | FGFR1HTTKDRSRCALDH1A1 | |
| SCHEMBL2189538 | 0.84 | HPGD (0.52) | FGFR1ALDH1A1 | |
| SCHEMBL31320827 | 0.83 | HPGD (0.56) | FGFR1KDRALDH1A1 | |
| SCHEMBL13871735 | 0.81 | HTT (0.66) | FGFR1HTT | |
| SCHEMBL2646079 | 0.79 | HPGD (0.47) | FGFR1ALDH1A1 | |
| SCHEMBL31261227 | 0.79 | FGFR1 (0.66) | FGFR1SRCALDH1A1 | |
| SCHEMBL7986978 | 0.79 | FGFR1 (1.00) | FGFR1HTTKDRSRC | |
| SCHEMBL12415689 | 0.78 | GABRA1 (0.58) | FGFR1KDR | |
| SCHEMBL2646141 | 0.78 | GABRA1 (0.57) | FGFR1KDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | XPO4, OR10J3, EPB41 | FGFR1 3775/4885HTT 4174/4885KDR 2584/4885 |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | FGFR1 163/4885HTT 513/4885KDR 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.